BTBD16 Inhibitors
BTBD16 inhibitors constitute a chemical class designed to suppress the activity of the BTBD16 protein, which plays a crucial role in various cellular processes. These inhibitors work by targeting specific interactions or signaling pathways that are essential for BTBD16 function. The mechanism of inhibition often involves the interference with protein-protein interactions that are critical for the proper functioning of BTBD16. For instance, some compounds within this class may prevent the binding of BTBD16 to other proteins or substrates it typically interacts with, hindering its role in cellular signaling or regulation. Others might interfere with the post-translational modifications of BTBD16, which are necessary for its activity. For example, if BTBD16 requires phosphorylation to be active, an inhibitor might obstruct the kinase responsible for adding this phosphate group, thereby maintaining BTBD16 in an inactive state. These actions ensure that the protein's activity is diminished without affecting its expression levels or the general pathways it is involved in.
Furthermore, BTBD16 inhibitors might also target the ubiquitination process. Since BTBD16 is a part of the BTB-domain-containing protein family, which is known to be involved in ubiquitin-mediated proteolysis, inhibitors might impede the protein's role in tagging other proteins for degradation. This could lead to an accumulation of proteins that BTBD16 would normally help to degrade, indirectly reducing BTBD16's functional activity through a buildup of its substrates. This class of inhibitors may also block the interaction of BTBD16 with E3 ubiquitin ligases, which are enzymes that work in tandem with BTBD16 to target proteins for degradation. By preventing these interactions, the inhibitors would cause a regulatory imbalance, impacting the protein turnover and signaling pathways where BTBD16 is implicated. Each molecule in this class of inhibitors is characterized by its unique binding affinity and specificity, ensuring that it effectively disrupts BTBD16's role without off-target effects on other proteins.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK). MEK is part of the MAPK/ERK pathway which is crucial for cell proliferation and differentiation. Inhibition of MEK leads to a reduction in ERK phosphorylation and activity. Since BTBD16 is implicated in processes that are regulated by the MAPK/ERK pathway, PD 98059 would indirectly lead to decreased functional activity of BTBD16 by dampening the pathway it relies on. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K). PI3K signaling is involved in various cellular functions including growth, proliferation, and survival. Inhibition of PI3K disrupts the PI3K/AKT pathway, which can affect protein functions downstream, including BTBD16, by limiting the pathway's ability to contribute to the protein's functional context. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another strong inhibitor of PI3K, like LY294002. By inhibiting PI3K, it suppresses the PI3K/AKT signaling pathway, which is known to have a broad range of effects on cellular processes including metabolism and survival. This suppression would, in turn, affect the functional activity of BTBD16, as the protein is associated with cellular processes governed by this pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is an inhibitor of the Rho-associated protein kinase (ROCK). ROCK is implicated in the regulation of the cytoskeleton, cell motility, and cell contraction. By inhibiting ROCK, Y-27632 could potentially decrease the mechanical stress on cells, which may affect the activity of BTBD16 if BTBD16's activity is modulated by such mechanical stress. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which is involved in the response to stress and inflammatory cytokines. If BTBD16 is involved in pathways responsive to stress signals mediated by p38 MAPK, then inhibition by SB203580 could lead to reduced activity of BTBD16. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which plays a role in the regulation of apoptosis, cytokine production, and T-cell differentiation. Should BTBD16 be involved in JNK-regulated processes, the use of SP600125 could decrease the functional activity of BTBD16 by inhibiting this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific inhibitor of the mammalian target of rapamycin (mTOR), which is central to cell growth and metabolism. Inhibition of mTOR by rapamycin could lead to a decrease in BTBD16 activity if BTBD16 is reliant on mTOR signaling for its functional state or expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which, like PD 98059, prevents the activation of MAPK/ERK pathway. This compound would also indirectly decrease the activity of BTBD16 by inhibiting a pathway that may be essential for its function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
GF 109203X is a potent inhibitor of protein kinase C (PKC). PKC plays a role in the regulation of cell proliferation and apoptosis. By inhibiting PKC, GF 109203X could affect BTBD16 activity if BTBD16 is involved in signaling pathways regulated by PKC. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
ZM 336372 is an inhibitor of Raf-1 kinase, which is part of the MAPK/ERK signaling cascade. The inhibition of Raf-1 would lead to a decrease in MAPK/ERK signaling, potentially affecting BTBD16's functional activity if BTBD16 is a downstream effector in this pathway. | ||||||